Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7X92

The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab445

Summary for 7X92
Entry DOI10.2210/pdb7x92/pdb
EMDB information33064
DescriptorSpike glycoprotein, Ab445 heavy chain, Ab445 light chain, ... (4 entities in total)
Functional Keywordssevere acute respiratory syndrome coronavirus-2 (sars-cov-2) spike trimer, covid-19, human neutralizing antibody, rbd, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus 2
More
Total number of polymer chains3
Total formula weight197327.85
Authors
Kamada, K.,Shirouzu, M. (deposition date: 2022-03-15, release date: 2022-12-07, Last modification date: 2022-12-21)
Primary citationTakeshita, M.,Fukuyama, H.,Kamada, K.,Matsumoto, T.,Makino-Okamura, C.,Uchikubo-Kamo, T.,Tomabechi, Y.,Hanada, K.,Moriyama, S.,Takahashi, Y.,Ishigaki, H.,Nakayama, M.,Nguyen, C.T.,Kitagawa, Y.,Itoh, Y.,Imai, M.,Maemura, T.,Furusawa, Y.,Ueki, H.,Iwatsuki-Horimoto, K.,Ito, M.,Yamayoshi, S.,Kawaoka, Y.,Shirouzu, M.,Ishii, M.,Saya, H.,Kondo, Y.,Kaneko, Y.,Suzuki, K.,Fukunaga, K.,Takeuchi, T.
Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models.
Iscience, 25:105596-105596, 2022
Cited by
PubMed Abstract: The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been highly effective. However, there remain few practical antibodies against viruses that are acquiring mutations. In this study, we created 494 monoclonal antibodies from patients with COVID-19-convalescent, and identified antibodies that exhibited the comparable neutralizing ability to clinically used antibodies in the neutralization assay using pseudovirus and authentic virus including variants of concerns. These antibodies have different profiles against various mutations, which were confirmed by cell-based assay and cryo-electron microscopy. To prevent antibody-dependent enhancement, N297A modification was introduced. Our antibodies showed a reduction of lung viral RNAs by therapeutic administration in a hamster model. In addition, an antibody cocktail consisting of three antibodies was also administered therapeutically to a macaque model, which resulted in reduced viral titers of swabs and lungs and reduced lung tissue damage scores. These results showed that our antibodies have sufficient antiviral activity as therapeutic candidates.
PubMed: 36406861
DOI: 10.1016/j.isci.2022.105596
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (4.1 Å)
Structure validation

226707

PDB entries from 2024-10-30

PDB statisticsPDBj update infoContact PDBjnumon